It relates to therapeutic agents and applications containing nucleic acid and CAR modified immune cells. The therapeutic agent comprises a first composition and a second composition. The first composition comprises a nucleic acid having a coding sequence of a labeled polypeptide for introduction into tumor cells and/or cancer cells； the labeled polypeptide has an operably linked The extracellular epitope, spacer and transmembrane portion can be expressed and modified on the surface of the tumor cell and/or cancer cell； the amino acid sequence of the extracellular epitope contains the amino acid sequence of one or more epitope polypeptides ； Wherein in the natural state, the amino acid sequence of the mammalian cell membrane protein or secreted protein does not contain the amino acid sequence of the epitope polypeptide； the second composition includes a chimeric antigen receptor modified immune cell； the chimeric antigen receptor The modified immune cells can specifically recognize and bind the extracellular epitope of the labeled polypeptide. The invention achieves synergistic curative effect.涉及包含核酸及CAR修飾的免疫細胞的治療劑及應用。該治療劑包含第一組合物和第二組合物，第一組合物包含用於導入腫瘤細胞和/或癌細胞的、具有標記性多肽編碼序列的核酸；該標記性多肽具有可操作地連接的胞外抗原決定區、間隔部分和跨膜部分，能夠經表達而修飾在該腫瘤細胞和/或癌細胞的表面；該胞外抗原決定區的氨基酸序列含有一或複數抗原表位多肽的氨基酸序列；其中在自然狀態下，哺乳動物細胞膜蛋白或分泌蛋白的氨基酸序列不含有該抗原表位多肽的氨基酸序列；該第二組合物包含嵌合抗原受體修飾的免疫細胞；該嵌合抗原受體修飾的免疫細胞能夠特異性識別並結合該標記性多肽的該胞外抗原決定區。本發明實現了協同療效。
